Fozinap tab 10mg 28 pcs kanonfarma

$5.54

Fozinap tab 10mg 28 pcs kanonfarma

5 in stock

Quantity:

Description

Composition
Active substance:
1 tablet contains: fosinopril sodium, 10.0 mg or 20 mg.
Excipients:
Colloidal silicon dioxide 0.7 mg Croscarmellose sodium 5 mg lactose monohydrate 66.8 mg, macrogol (polyethylene glycol 4000) 0.5 mg Sodium stearyl fumarate 1 mg, 7 mg povidone, microcrystalline cellulose 47.88 mg Calcium stearate 1 12 mg.
Description:
Tablets round, Valium, with a facet and Valium (dosage 10 mg); round, beveled Valium (dosage 20 mg), a white or nearly white. Allowed marbling.
Product form:
Tablets of 10 mg and 20 mg.
At 7, 10, 15 or 30 tablets in blisters of PVC film and aluminum foil printed patent.
1, 2, 4, 8 blisters of 7 tablets or 1, 3 blisters with 10 tablets, or 1, 2 blisters 15 tablets or 1 contour blister of 30 tablets together with instructions for use in a pile of cardboard.
Contraindications
Hypersensitivity to fosinopril and other ingredients; hereditary angioedema or idiopathic; angioedema the application of other ACE inhibitors (history); pregnancy; lactation (breast feeding); age 18 years (effectiveness and safety have been established); lactose intolerance, lactase deficiency or glucose-galaktaznaya malabsorption.
With careful use in renal failure; hyponatremia (risk of dehydration, hypotension, chronic renal failure); bilateral renal artery stenosis or stenosis of the artery to a solitary kidney; aortic stenosis; condition after kidney transplantation; with desensitization; systemic connective tissue diseases (including systemic lupus erythematosus, scleroderma), due to increased risk of neutropenia and agranulocytosis; hemodialysis; cerebrovascular disorders (including cerebral circulatory insufficiency); coronary heart disease; chronic heart failure III-IV NYHA functional class classification; diabetes; suppression of bone marrow hematopoiesis; hyperkalemia; in elderly patients; gout; against the background of a diet with restriction of salt; under conditions involving decrease of blood volume (including diarrhea, vomiting, diuretics previous treatment).
Dosage
10 mg
Indications
Arterial hypertension (as monotherapy or in combination therapy);
Chronic heart failure (in a combination therapy).
Interaction with other drugs
The simultaneous use of antacids may reduce absorption (including hydroxide, magnesium aluminum hydroxide) fosinopril (fosinopril and said means should be taken at intervals of not less than 2 hours).
Patients receiving fosinopril concurrently with drugs lithium may increase the concentration of lithium in blood plasma and the risk of lithium toxicity (necessary to monitor the concentration of lithium in blood plasma).
When assigning fosinopril should be noted that indomethacin and other non-steroidal anti-inflammatory drugs (including aspirin at a dose of greater than 3 g, and inhibitors of cyclooxygenase-2) can decrease the antihypertensive effect of ACE inhibitors, particularly in patients with low-renin hypertension.
When the joint application of fosinopril with diuretics or in combination with a strict diet, limiting sodium intake or hemodialysis may develop severe arterial hypotension, particularly in the first hour after taking the initial dose of fosinopril.
When the joint application of fosinopril with potassium preparations, potassium-sparing diuretics (including with amiloride, spironolactone, triamterene), with food supplements containing potassium, increases the risk of hyperkalemia. Patients with chronic heart failure, diabetes, simultaneously receiving potassium-sparing diuretics, potassium, kalisodergaszczye salt substitutes or other means for causing hyperkalemia (e.g., heparin), ACE inhibitors increase the risk of hyperkalemia.
Fosinopril enhances hypoglycemic effect sulfonylureas, insulin.
While the use of allopurinol, cytostatic agents, immunosuppressants, procainamide increased risk of leucopenia.
Estrogens weaken hypotensive effect of fosinopril because of its ability to hold up liquid.
Antihypertensive agents, opioid analgesics, drugs for general anesthesia enhances the hypotensive effect of fosinopril.
Bioavailability fosinopril while the use of chlorthalidone, nifedipine, propranolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline bromide, digoxin, aspirin and warfarin does not change.
Overdose
Symptoms: marked reduction of blood pressure, bradycardia, shock, disruption of water and electrolyte status, acute renal failure, stupor.
Treatment: the drug should be stopped, shown gastric lavage, adsorbents (e.g., activated carbon), vasopressor agents, infusion of 0.9% sodium chloride solution and more symptomatic and supportive treatment. The use of hemodialysis ineffective.
pharmachologic effect
Pharmacological group:
An angiotensin-converting enzyme (ACE).
Pharmacodynamics:
ACE inhibitor. It has a hypotensive, vasodilatory, diuretic and potassium-sparing effect. Fosinopril prevents the conversion of angiotensin I to the vasoconstrictor compound angiotensin II, resulting vasopressor activity and reduced aldosterone secretion, which can result in a slight increase in the content of potassium ion in serum with simultaneous loss of body fluids and sodium ions. As a result of decreasing total peripheral vascular resistance and systemic arterial pressure (BP). It inhibits the synthesis of aldosterone with ACE inhibits tissue.
Fosinopril inhibits metabolic degradation of bradykinin, which has powerful vasopressor action; at the expense of the antihypertensive effect of the drug may be enhanced.
Decrease in blood pressure are not accompanied by changes in circulating blood volume, cerebral and renal blood flow, blood supply to internal organs, skeletal muscle, skin, the reflex activity of the myocardium. When hypertension and left ventricular hypertrophy treatment leads to a decrease in left ventricular mass and a decrease in ventricular septal thickness. Long-term therapy does not lead to metabolic disorders. After oral hypotensive effect develops over 1 hour, reaching a maximum after 3 – 6 hours and stored for 24 hours.
In chronic heart failure the positive effects of fosinopril are obtained mainly by suppressing the activity of the renin-aldosterone system. Inhibition of ACE reduces both preload and afterload on the myocardium.
Fosinopril promotes exercise tolerance, reducing the severity of chronic heart failure.
Pharmacokinetics:
After oral absorption from the gastrointestinal tract is about 30-40%. The extent of absorption is independent of food intake, but the rate of absorption can be slowed.
Metabolism fosinopril by the enzymes to form fozinoprilata occurs mainly in the liver and in the mucosa of the gastrointestinal tract.
The time to reach maximum concentration in plasma fozinoprilata is 3 hours and is independent of the dose.
Communication with plasma proteins – more than 95%. Fozinoprilat has a relatively small volume of distribution, and to a small extent with the associated cellular components of blood. It does not cross the blood-brain barrier.
Fosinopril excreted equally through the liver and kidneys. When hypertension patients with normal renal function and liver fozinoprilata half-life is approximately 11.5 hours. In chronic heart failure the half-life is 14 hours.
Pregnancy and breast-feeding
Fozinap® is contraindicated for use during pregnancy. Use of the drug in the II and III trimester of pregnancy causes damage or death of the developing fetus. Of newborns whose mothers took ACE inhibitors during pregnancy, careful monitoring is recommended for early detection of arterial hypotension, oliguria and hyperkalemia.
Since Fozinap® excreted in breast milk, with the need to use during lactation discontinue breastfeeding.
Conditions of supply of pharmacies
On prescription.
side effects
Cardio-vascular system: marked reduction of blood pressure, orthostatic hypotension, collapse, tachycardia, palpitations, arrhythmias, angina, myocardial infarction, “tides” of blood to the skin, fainting, cardiac arrest.
From the urinary system: development or exacerbation of the symptoms of chronic renal failure, proteinuria.
On the part of the central and peripheral nervous system: stroke, ischemia, cerebrovascular disease, dizziness, headache, fatigue, impaired memory; when used in high doses – insomnia, anxiety, depression, confusion, drowsiness, paresthesia.
From the senses: hearing and visual impairment, tinnitus.
From the digestive system: nausea, diarrhea, ileus, pancreatitis, hepatitis, cholestatic jaundice, abdominal pain, vomiting, constipation, anorexia, stomatitis, glossitis, dysphagia, flatulence, appetite disorders, weight change, dry mouth; intestinal swelling (very rare).
From respiratory system: a “dry” cough, pulmonary infiltrates, bronchospasm, dyspnea, rhinorrhea, sore throat, hoarseness, epistaxis.
From the side of hematopoiesis: lymphadenitis.
From the musculoskeletal system: arthritis.
From a metabolism: gout.
Allergic reactions: skin rash, pruritus, angioedema.
From the laboratory parameters: hypercreatininemia, increasing concentrations of urea, increased activity of “liver” transaminases, hyperbilirubinemia, hyperkalemia, hyponatremia; decrease in the hematocrit and hemoglobin concentration, increased erythrocyte sedimentation rate, leukopenia, neutropenia, eosinophilia.
Effect on the fetus: violation of fetal kidneys, reduced blood pressure of the fetus and newborn, renal dysfunction, hyperkalemia, hypoplasia of bones of the skull, oligohydramnios, contractures limbs, lung hypoplasia.
special instructions
Before treatment requires an analysis of earlier antihypertensive therapy, a degree of increase in blood pressure, limit salt diet and / or liquid, and other clinical situations.
If possible, discontinue the previously wire antihypertensive treatment for a few days before the start of treatment Fozinap®.
To reduce the likelihood of hypotension diuretic should be discontinued for 2-3 days prior to treatment with Fozinap®.
Before and during the treatment with Fozinap® need to control blood pressure, renal function, the content of potassium ions, creatinine, urea, electrolytes and activity concentration “liver” transaminases in blood.
It reported on the development of angioedema in patients while taking fosinopril. When propagating edema tongue, pharynx or larynx may develop airway obstruction which can be fatal. In the case of such reactions should stop taking the drug and to take measures of emergency treatment, including enter epinephrine solution subcutaneously (epinephrine) (1: 1000).
While receiving ACE inhibitors rarely observed swelling of the intestinal mucosa. Swelling of the mucous membrane of the intestine should be considered in the differential diagnosis in patients with complaints of abdominal pain during treatment with ACE inhibitors. Symptoms disappeared after discontinuation of ACE inhibitors.
The therapy of ACE inhibitors of anaphylactic reactions may develop during hemodialysis vysokoprotochnyh through the membrane, as well as during low density lipoprotein plasmapheresis with adsorption on dextran sulfate. In such cases, you should consider using another type of dialysis membrane or other medication.
Possible development of agranulocytosis and bone marrow suppression during treatment with ACE inhibitors. These events are more frequent in patients with impaired renal function, especially in the presence of systemic connective tissue diseases (including systemic lupus erythematosus or scleroderma). Before initiation of therapy with ACE inhibitors in the treatment process is carried out the total number of white blood cells and leukocyte control (1 per month in the first 3-6 months of treatment in the first year of use of the drug in patients with increased risk of neutropenia).
Symptomatic hypotension when used ACE inhibitors most often develops in patients after intensive treatment with diuretics, diet, limiting salt intake, or during kidney dialysis. Transient hypotension is not a contraindication for further use of the drug.
In hypertensive patients with bilateral renal artery stenosis or artery stenosis single kidney, and while the use of diuretics in patients with intact renal function during treatment with ACE inhibitors may increase the concentration of urea nitrogen and serum creatinine. If these effects persist after cessation of treatment, it is necessary to reduce the dose of the drug Fozinap® and / or a diuretic.
In some cases, patients with severe chronic heart failure treatment with ACE inhibitors may cause more marked antihypertensive effect, which can lead to oliguria or azotemia fatal. Therefore, the treatment of chronic heart failure drug Fozinap® necessary to monitor patients, especially during the first 2 weeks of treatment, as well as any increase in the dose or Fozinap® diuretic.
When expressed appreciable yellowness and increased activity “liver” transaminases Fozinap® drug therapy should be discontinued and appropriate treatment.
ACE inhibitors may enhance the hypotensive effect of agents used for general anesthesia. Prior to surgery (including dental) is necessary to prevent an anesthesiologist on the use of ACE inhibitors.
Caution should be exercised during exercise or in hot weather because of the risk of dehydration and hypotension due to a decrease in circulating blood volume.
Effects on ability to drive vehicles and management mechanisms
Care must be taken when driving or performing other work requiring attention, t. K. Dizziness may develop, especially after receiving the starting dose of the drug Fozinap®.
Storage conditions
In a dry, dark place at a temperature not higher than 25 C. Keep out of reach of children.
Dosing and Administration
The drug is administered by mouth, regardless of the meal. Take without chewing, with a small amount of liquid. Dose set individually.
When hypertension recommended starting dose is 10 mg 1 time / day. The dose should be adjusted depending on the dynamics of blood pressure lowering. Doses ranged from 10 to 40 mg 1 time / day. The maximum daily dose is 40 mg.
In chronic heart failure, the recommended starting dose is 5 mg (2.1 10 mg tablets) 1 or 2 times / day. The maximum daily dose is 40 mg / day.
Patients with impaired renal function and / or liver, as well as elderly patients correction mode is not required.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

KANONFARMA

There are no reviews yet.

Add your review